You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Sign In
UNLOCKING THE POTENTIAL OF BLOOD
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{d.Title}}
{{psData[masterIndex].blurb}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{n.blurb}}
{{s.Title}}
{{l.Title}}
Welcome, {{userName}}
{{'MP_HEADER_LOG_IN' | translate}}
{{countryCode}}
{{'SEARCH_MODAL_TITLE' | translate}}
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{c.Title}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{s.Title}}
{{l.Title}}
Page Content
QUICK LINKS
Get Product Support
Find Technical Documents
Find Certificates of Compliance
Get Training
Start a Career With Us
LATEST NEWS
New Collaboration with StafaCT Will Optimize Patient Pathways for Cellular Treatments
Terumo BCT Announces Enrollment of the First Patient in Its U.S. Clinical Trial Designed to Study Platelets Treated With the Mirasol
®
Pathogen Reduction Technology (PRT) System
Collaborative Global Effort to Advance Blood Safety Moves Forward Across Ghana
Terumo BCT's Spectra Optia
®
Apheresis System Is the First and Only Device on the European Market Indicated to Treat Guillain-Barré Syndrome and Myasthenia Gravis using Therapeutic Plasma Exchange